From: Persistence with treatment for Wilson disease: a retrospective study
Description | Persistent | Non-persistent | P value for persistent vs. non-persistent |
---|---|---|---|
Symptoms, n (%) | |||
Hepatic (n = 79) | 57 (45.2) | 22 (50.0) | 0.59 |
Neurological (n = 91) | 69 (54.8) | 22 (50.0) | |
Gender, n (%) | |||
Male (n = 77) | 53 (42.1) | 24 (54.5) | 0.15 |
Female (n = 93) | 73 (57.9) | 20 (45.5) | |
Adverse events, n (%) | |||
Yes (n = 61) | 43 (34.1) | 18 (40.9) | 0.42 |
No (n = 109) | 83 (65.9) | 26 (59.1) | |
Drug used, n (%) | |||
D-penicillamine (n = 76) | 57 (45.2) | 19 (43.2) | 0.81 |
Zinc sulphate (n = 94) | 69 (54.8) | 25 (56.8) | |
Treatment duration, mean ± SD, years | 11.7 ± 3.2 | 11.6 ± 3.0 | 0.81 |
Educational level, n (%) | |||
Vocational education | 29 (23.0) | 11 (25.0) | |
Upper secondary/post secondary | 51 (40.5) | 27 (61.4) | 0.01 |
Higher education | 46 (36.5) | 6 (13.6) | |
Family knowledge about WD, n (%) | |||
Minimal | 4 (3.2) | 4 (9.1) | |
Little | 21 (16.7) | 12 (27.3) | 0.14 |
Moderate | 42 (33.3) | 12 (27.3) | |
Good | 59 (46.8) | 16 (36.4) | |
Family position towards treatment, n (%) | |||
Negative | 0 | 0 | < 0.001 |
Neutral | 16 (12.7) | 18 (40.9) | |
Supportive | 110 (87.3) | 26 (59.1) |